Core Viewpoint - CeriBell, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its focus on transforming the diagnosis and management of serious neurological conditions [1][2]. Group 1: Company Overview - CeriBell, Inc. is a medical technology company dedicated to improving the diagnosis and management of patients with serious neurological conditions [3]. - The company has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed for acute care settings [3]. - The Ceribell System combines portable hardware with AI-powered algorithms for rapid diagnosis and continuous monitoring of neurological conditions [3]. - The system is FDA-cleared for detecting seizures and delirium in intensive care units and emergency rooms across the U.S. [3]. Group 2: Upcoming Event - Jane Chao, Ph.D., CEO and Co-founder of CeriBell, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 9:00 am PST / 12:00 pm EST [1][2]. - A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website [2].

Core Viewpoint - Treace Medical Concepts, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its innovative approach in the surgical treatment of bunions and related midfoot deformities [1] Group 1: Company Overview - Treace Medical Concepts is a medical technology company focused on improving surgical management standards for bunions and midfoot deformities, which affect approximately 67 million Americans [4] - The company estimates that 1.1 million Americans are annual surgical candidates for bunion treatment [4] - Treace has developed the patented Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions by correcting deformities in all three planes and stabilizing the affected joint [4] Group 2: Product Offerings - In addition to the Lapiplasty system, Treace offers the Adductoplasty Midfoot Correction System for midfoot deformities and two minimally invasive osteotomy systems: the Nanoplasty 3D and the Percuplasty™ systems [4] - The company also provides the SpeedMTP MTP Fusion System and is expanding its SpeedPlate rapid compression implant platform for new applications [4] - Treace enhances surgical planning with its IntelliGuide™ technology, which offers patient-specific pre-operative planning and cut guide solutions [4] Group 3: Investor Relations - Treace encourages investors to regularly check its website for important updates and information [3] - A live webcast of the upcoming presentation will be available on the company's investor relations website [2]

TABLE OF CONTENTS REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 30, 2025 Registration No. 333-290244 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENCORE MEDICAL, INC. (Exact name of registrant as specified in its charter) 3841 (Primary Standard Industrial Classification Code Number) Minnesota (State or other jurisdiction of inc ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, a decrease from the previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3]. Legal Representation - Bleichmar Fonti & Auld LLP, a leading international law firm, is representing the plaintiffs in this class action lawsuit, having a strong track record in securities class actions and shareholder litigation [8].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would be met once inventory was available [5]. - Contrary to these assurances, Inspire failed to adequately prepare clinicians and payors, leading to delays in adoption and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Insights - Establishment Labs (ESTA) has submitted its Motiva breast implants to the FDA for approval in primary and revision breast reconstruction, expanding its market beyond elective procedures [1][9] - The submission is part of the company's strategy to utilize existing clinical data and early commercial traction to enter a less innovation-heavy segment of breast care, potentially leading to more stable growth [2][4] Company Developments - If approved, the reconstruction indication could significantly enhance Establishment Labs' business by tapping into a reimbursement-backed market with steadier procedure volumes compared to elective augmentation [4] - ESTA's current market capitalization stands at $2.22 billion, with projected earnings growth of 54.84% for the next year [5] - The FDA submission is supported by a 274-patient IDE study conducted across 17 U.S. sites and one in Europe, evaluating the safety and performance of Motiva implants in post-mastectomy reconstruction [10][12] Product Details - The filing includes Motiva SmoothSilk Round and Ergonomix implants, which feature patented SmoothSilk surface technology for enhanced biocompatibility and reduced inflammatory response [11] - Since gaining FDA approval for breast augmentation in 2024, over 60,000 Motiva implants have been sold in the U.S., and the company has a commercial presence in reconstruction through the Motiva Flora tissue expander [12] Industry Outlook - The global breast implants market was estimated at $2.66 billion in 2024 and is projected to reach $5.16 billion by 2033, growing at a CAGR of 7.7% from 2025 to 2033, driven by rising demand for aesthetic procedures and technological advancements [13]

We recently compiled a list of the 7 Most Promising Robotics Stocks According to Wall Street Analysts. Medtronic plc stands fifth among the most promising stocks.  TheFly reported on December 18 that Truist Securities maintained its Hold recommendation on MDT but lowered its price objective to $107.00 from $110.00. This revision followed an update to the firm’s valuation models for the medical device sector. Analyst Richard Newitter noted that while MDT’s long-term growth prospects remain intact, the near ...

Core Viewpoint - The announcement highlights the successful one-year follow-up results of the early feasibility study for the AltaValveTM transcatheter mitral valve replacement (TMVR) device developed by 4C Medical Technologies, Inc., indicating significant improvements in patient outcomes and safety [1] Group 1: Study Overview - The study involved 30 high-risk patients with symptomatic severe mitral regurgitation (MR) across multiple centers in Europe, the USA, and Japan [1] - Patients were divided into two groups: 13 underwent the transapical approach, while 17 used the transseptal approach [1] Group 2: Clinical Outcomes - The technical success rate of the procedure was reported at 97%, with complete elimination of MR in all patients [1] - The mean transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-operation, indicating significant hemodynamic improvement [1] Group 3: Safety Profile - The one-year all-cause mortality rate was 17% for the transapical group and only 7% for the transseptal group, with no cases of cardiac-related mortality [1] - No adverse events such as stroke, new-onset atrial fibrillation, or mitral valve re-intervention were reported in the entire cohort [1] Group 4: Quality of Life Improvement - 96% of patients improved to NYHA functional class I-II at one year, reflecting a substantial enhancement in quality of life [1] Group 5: Regulatory Status - AltaValveTM received two breakthrough device designations from the FDA in 2024 and is currently conducting pivotal clinical studies in Europe and the USA under an FDA-approved Investigational Device Exemption (IDE) [1]

Group 1 - The core focus for dividend investors is not only high yield but also the reliability of that yield over the long term, which is challenging to find [1] - The healthcare sector presents solid options for dividend-paying stocks, including Bristol Myers Squibb, Medtronic, and Johnson & Johnson, with yields up to 4.6% [1][4] - Economic factors such as inflation can erode the purchasing power of dividend income, making it essential to choose companies with growth potential and a history of dividend increases [2] Group 2 - The healthcare industry is driven by innovation and population growth, with rising socio-economic conditions leading to increased demand for medical products [3] - Bristol Myers Squibb has a dividend yield of 4.6% but faces challenges due to patent expirations on blockbuster drugs, which raises concerns among investors [7] - Medtronic is approaching Dividend King status, while Johnson & Johnson has a strong track record with over 50 annual dividend increases [7]

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott’s proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low. For a free consultation, please visit https://julieholleman.com/exact-sciences-corp/, or contact partner Scott Holleman at (929) 415-1020 or by email at scott@julieholleman.com. The deal was announced i ...